{
  "scenario_id": "BAL-LARGE3-0053",
  "variant_type": "balance_large_scale_v3",
  "title": "Antiviral Therapeutic Development: AI-Driven Approaches",
  "context": {
    "prior_knowledge": "Basic Life Sciences Knowledge or Experience in Pharmaceutical-Related Tasks",
    "duration": "Short-term intensive (within 1 week)",
    "learning_environment": "Mobile microlearning",
    "class_size": "Large (30+ learners)",
    "additional_context": "Work-integrated training for employees to understand virus treatment development processes",
    "institution_type": "Corporate/Enterprise",
    "learner_age": "40s and above",
    "learner_education": "Adult learner (non-degree)",
    "learner_role": "Office worker (administrative/management)",
    "domain_expertise": "Intermediate"
  },
  "learning_goals": [
    "Learners can explain virus infection mechanisms and therapeutic development stages.",
    "Within 1 week, learners explain 3 core features of single-domain antibodies (sdAbs) (small size, high stability, single-domain structure), sequentially list the 4 stages of AI-based antibody development (target identification → virtual screening → molecular design → experimental validation), and specify AI technologies (e.g., AlphaFold, Rosetta) used in each stage.",
    "Learners apply initial therapeutic evaluation methods, including ELISA and neutralization assays."
  ],
  "constraints": {
    "budget": "medium",
    "resources": [
      "Mobile Learning Platform",
      "Interactive Simulation Tool",
      "Case Analysis Materials"
    ],
    "accessibility": null,
    "language": "en",
    "tech_requirements": "Digital devices provided",
    "assessment_type": "Formative assessment-focused"
  },
  "difficulty": "Easy - Simple structure with minimal constraints",
  "domain": "AI"
}